Post Hoc Live: How the US can compete with China biotech, with Scott Gottliebnews2025-09-25T18:51:41+00:00September 25th, 2025|Endpoints News|
Avenzo collects another $60M for two small molecules and two ADCs licensed from Chinanews2025-09-22T13:00:50+00:00September 22nd, 2025|Endpoints News|
Endpoints 11 winner 2025: Sironax swings big in neurology as China biotech risesnews2025-09-19T14:00:13+00:00September 19th, 2025|Endpoints News|
Joe Jimenez’s new biotech inks up to $1B biobuck deal for Mabwell’s cardio siRNAnews2025-09-17T13:32:58+00:00September 17th, 2025|Endpoints News|
Ollin lands $100M to test eye drugs from Chinese partners and bring in more assetsnews2025-09-17T10:30:15+00:00September 17th, 2025|Endpoints News|
Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 studynews2025-09-10T13:39:50+00:00September 10th, 2025|Endpoints News|
Summit plays defense for the first time as questions loom over Phase 3 datanews2025-09-08T19:01:44+00:00September 8th, 2025|Endpoints News|
#WCLC25: Summit reports full Phase 3 data from first group of Western lung cancer patientsnews2025-09-07T07:30:43+00:00September 7th, 2025|Endpoints News|
BioNTech and DualityBio’s ADC hits in late-stage breast cancer trial in Chinanews2025-09-05T11:04:34+00:00September 5th, 2025|Endpoints News|
Hengrui does another US deal, this time in Cytokinetics’ cardio arenanews2025-09-05T08:01:47+00:00September 5th, 2025|Endpoints News|
